Forbius is engaged in the designing and development of advanced biotherapeutics to treat cancer and fibrotic diseases. The company has developed a portfolio of selective and potent inhibitors
Today’s action follows the FDA’s extensive review of the science and data generated over the past several months stemming from efforts to facilitate emergency access to convalescent plasma
Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group and its affiliates, has signed an agreement to acquire Takeda’s wholly-owned subsidiary Takeda Consumer Healthcare
The newly released manuscript describes key safety and immunogenicity data from the U.S. Phase 1 trial for the BNT162b2 vaccine candidate, which at 30μg recorded 7 days after
The approval allows Kesimpta to be used as an injection for subcutaneous use to treat RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in
With a grant totaling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of
Situated in Frederick of Colorado, the advanced facility is engaged in the development and manufacturing of oligos that are short DNA and RNA molecules used for the creation
The trial was a randomized, double-blind, placebo-controlled, multi-center, dose escalation study assessing the safety and efficacy of F351 for Hepatic Fibrosis in Chronic Viral Hepatitis B patients in
In October 2018, the companies first announced their collaboration for the discovery, development and commercialisation of advanced targeted immuno-oncology treatments for cancer. As part of the expanded multi-year
Enspryng is administered subcutaneously every four weeks**. Enspryng was granted Breakthrough Therapy Designation in December 2018 and the US Biologics License Application (BLA) was filed in August 2019
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.